Effects of the combination of magnesium bisphosphonates versus bisphosphonates alone on bone remodeling:Randomized pilot clinical trial - MAGELLA

niversity Hospital of Clermont-Ferrand0 个研究点目标入组 48 人开始时间: 2021年12月3日最近更新: 2022年3月2日

适应症

试验速览

暂无简介。

•- Woman aged 50 or over, suffering from postmenopausal osteoporosis, fracture or not, requiring the initiation of treatment with injectable bisphosphonates as part of the care.
•- Able to give informed consent to participate in research.
•- Affiliation to a French Social Sregimen
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 48

•- Initial densitometry more than a year old.
•- Patient receiving a treatment or food supplement containing magnesium.
•- Contraindication to the administration of Mg: hypersensitivity to magnesium carbonate or to any of the excipients.
•- Patient with magnesium> 1.07 mmol / l,
•- Patient with chronic renal failure, defined by a glomerular filtration rate <30 mL.min – 1 estimated by CKD-EPI
•- Patient with a medical and / or surgical history judged by the investigator or his representative to be incompatible with the test.
•- Patient under legal protection or deprived of liberty.
•- Refusal of participation.

发起方

niversity Hospital of Clermont-Ferrand